JH-RE-06
Based on 4 publication(s) in Google Scholar
JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 1361227-90-8
- Formula: C20H16Cl3N3O4
- Molecular Weight:468.72
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) JH-RE-06
More
Customer Validation & Images
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
-
WB
-
IHC
-
IF
All DNA/RNA Synthesis Isoforms
More
Biological Activity
JH-RE-06 unexpectedly induces dimerization of the REV1 CTD at its REV7-binding surface and blocks the REV1-REV7 interaction[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1361227-90-8
-
Appearance Solid
-
Molecular Weight 468.72
-
Formula C20H16Cl3N3O4
-
Color White to yellow
-
SMILES
O=C1C(C(CC(C)C)=O)=C(NC2=C(Cl)C=C(Cl)C=C2)NC3=C1C([N+]([O-])=O)=CC=C3Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection. [Abstract]2025 Dec 7. PMID: 41354653
JH-RE-06 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 7. [Abstract]
Quantification of the percentage of AnnexinV/PI +ve cells assessed by flow cytometry in EP300Mut, EP300WT NA-ATLL cells +/− REV1i (10 μM JHRE06 (JH-RE-06) for 24 h) and +/− PARPi (10 μM Olaparib for 72 h), N = 3.
-
Oncol Rep
REV1‑targeting inhibitor JH‑RE‑06 induces ferroptosis via NCOA4‑mediated ferritinophagy in colorectal cancer cells. [Abstract]2025 Dec;54(6):159. PMID: 40999956
JH-RE-06 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2025 Dec;54(6):159. [Abstract]
Cell viability assessed by Cell Counting Kit-8 revealed differential sensitivity to JH (JH-RE-06) (0.5-5 µM; 24-72 h), with sustained effects observed at 72 h vs. 24 h in CRC models.
JH-RE-06 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2025 Dec;54(6):159. [Abstract]
WB analysis was used to detect γH2AX levels in cells treated with JH (JH-RE-06) for 24 h. For HCT116 cells, JHL represents 1.5 and JHH represents 3.0 µM JH. For SW620 cells, JHL represents 1.0 and JHH represents 1.5 µM JH. Concentrations were selected based on treatments that resulted in ~50% cell viability after 24 or 72 h. GAPDH was used as the internal control.
JH-RE-06 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2025 Dec;54(6):159. [Abstract]
Representative immunohistochemical images of PCNA and Ki-67 staining in tumor sections. Scale bar, 50 µm. The results showed that JH-RE-06 (1.6 mg/kg; i.t.; once every 48 h, 20 doses in total) significantly suppressed tumor growth and blood vessel formation.
JH-RE-06 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2025 Dec;54(6):159. [Abstract]
Immunofluorescence staining of γH2AX in HCT116 cells treated with 3.0 µM JH (JH-RE-06) and/or 5.0 µM OXA for 12 and 24 h. Scale bar, 20 µm.
JH-RE-06 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2025 Dec;54(6):159. [Abstract]
Gross appearance of tumors and tumor growth curves for OXA‑resistant HCT116 cell xenografts in mice. The results showed that the JH-RE-06 (1.6 mg/kg; i.t.; once every 48 h, 20 doses in total) group displayed a substantial reduction in tumor volume, indicating its effectiveness against OXR malignancies .
JH-RE-06 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2025 Dec;54(6):159. [Abstract]
HCT116 and treated with JHL (JH-RE-06) (1.5 µM) and JHH (3.0 µM) for 24 h show intracellular vacuolar changes, with mitochondria-like structures undergoing digestion inside the vacuoles. Scale bar, 5 µm.
JH-RE-06 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2025 Dec;54(6):159. [Abstract]
HCT116 cells treated with 3.0 µM JH (JH-RE-06) at 6, 12 and 24 h post-treatment. The results showed that intracellular free Fe2+ levels increased following 6 h treatment, peaking at 24 h in HCT116 cells. Concurrently, levels of the lipid oxidation marker MDA increased, while GSH levels decreased over time.
-
-
Solvent & Solubility
DMSO : 100 mg/mL (213.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.33 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1335 mL | 10.6673 mL | 21.3347 mL | 53.3367 mL |
| 5 mM | 0.4267 mL | 2.1335 mL | 4.2669 mL | 10.6673 mL | |
| 10 mM | 0.2133 mL | 1.0667 mL | 2.1335 mL | 5.3337 mL | |
| 15 mM | 0.1422 mL | 0.7112 mL | 1.4223 mL | 3.5558 mL | |
| 20 mM | 0.1067 mL | 0.5334 mL | 1.0667 mL | 2.6668 mL | |
| 25 mM | 0.0853 mL | 0.4267 mL | 0.8534 mL | 2.1335 mL | |
| 30 mM | 0.0711 mL | 0.3556 mL | 0.7112 mL | 1.7779 mL | |
| 40 mM | 0.0533 mL | 0.2667 mL | 0.5334 mL | 1.3334 mL | |
| 50 mM | 0.0427 mL | 0.2133 mL | 0.4267 mL | 1.0667 mL | |
| 60 mM | 0.0356 mL | 0.1778 mL | 0.3556 mL | 0.8889 mL | |
| 80 mM | 0.0267 mL | 0.1333 mL | 0.2667 mL | 0.6667 mL | |
| 100 mM | 0.0213 mL | 0.1067 mL | 0.2133 mL | 0.5334 mL |
Powered by Bioz